PYXS
Pyxis Oncology·NASDAQ
--
--(--)
--
--(--)
8.73 / 10
Outperform
Fund flow metrics score 7.46/10, revealing robust fund flow characteristics. Beneficial overall, block, Large, and Extra-large trends are challenged by problematic Small and Medium signals, indicating positive capital movement. Analyst sentiment reflects overwhelmingly bullish analyst consensus with strong conviction. The rating profile includes Strong Buy(100.0%) from 2 analytical reports, supported by 10.00 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-24
InstitutionStifel
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for PYXS?
- PYXS holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 8.73/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
